Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

A French technology transfer office offers a method of treatment and prevention of torsades de pointes for women.

Country of Origin: France
Reference Number: TOFR20181025001
Publication Date: 25 October 2018

Summary

The French TTO (Technology Transfer Office) is acting on behalf of major hospital and research group of the Paris region that has designed and patented a new method of treatment and prevention of torsades de pointes for women.  The French public research centre is looking for interested pharmaceutical companies for a technical cooperation or a license agreement.

Description

A French Technology Transfer Office (TTO) is acting on behalf a major hospital and research group in the Paris region that has designed method of treatment and prevention of torsades de pointes for women.

* Market challenges :
Torsades de pointes are accelerations of heart rhythm that follow a disorder of the ventricular repolarization called long QT. In cardiology, the QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. Women have a longer QT than men, which is currently attributed to differences in hormonal expression although the underlying mechanisms are not fully understood. Many drugs increase the QT, which correlates with the endogenous risk predisposing women, resulting in a considerable increase in the probability of occurrence of these torsades de pointes. Torsade is a life-threatening arrhythmia and may present as sudden cardiac death in patients with structurally normal hearts.

* State of the art :
The treatment consists in using a drug called beta-adrenergic antagonists at maximally tolerated doses as a first-line long-term therapy in congenital long QT syndrome. Beta-adrenergic antagonists belong to the class of Beta blockers. That class of medications are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack after a first heart attack. Propranolol is used most extensively, but other agents such as esmolol or nadolol also can be used.

But those treatments should be avoided in some particular congenitals cases which bradycardia is a prominent feature and are contraindicated in acquired long QT syndrome because bradycardia produced by these agents can precipitate torsade.

* Proposed technology :
The method relies on the use of compounds, normally taken as progestin drugs (contraceptives), for the treatment and prevention of torsade de pointes recurrence. This method is recommended after the occurrence of an endogenous (congenital) or exogenous triggering factor, such as taking a drug.

*Partnership :
The partner sought could be a company interested in :
- a license agreement as the TTO is ready to negociate directly the patents rights for specific applications, or
- a technical cooperation agreement if the industrial application can benefit directly from the actual technology to developp a treatment.

*Keywords :
#Cardiology
#Torsades de pointes
#QT
#progestin

Advantages and Innovations

The main advantage of this new method is that it works for both congenital and acquired torsades de pointes.

It also avoids previous tests before giving some drugs to patient.

Stage Of Development

Under development/lab tested

Stage Of Development Comment

The technology has been tested but remains as pre-proof of concept. Technical developpments have to be done in order to finalize the treatment.

Requested partner

The TTO is looking for an industrial partner for developping and commercializing the technology.

The partner sought could be a pharmaceutical company interested in :

- a licencing agreement as the TTO is ready to negotiate directly the patents rights for specific applications.

- a technical cooperation. The eventual partner should have a clear industrial application in mind and a strong technical background to co-develop a treatment.

Kooperationsanfrage stellen